Reproduction and energy balance: the integrative role of prolactin

Романцова, Т. И.

doi:10.14341/omet201415-18

Cited by 10 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…На синтез и секрецию пролактина оказывает влияние большое количество биологически активных веществ. В частности, дофамин является ингибитором синтеза пролактина, а к числу его активаторов относятся эстрогены, гонадотропин-рилизинг гормон, серотонин, окситоцин, вазопрессин, эндогенные опиоиды и другие соединения [15]. Таким образом, учитывая нарушение нормального паттерна секреции гонадотропин-рилизинг гормона и низкие уровни эстрадиола при ЦГ у женщин, лактотрофы гипофиза не получают адекватного активирующего влияния и синтез пролактина снижается.…”

Section: Discussionunclassified

Basal level of luteinizing hormone as a key marker of the idiopathic central hypogonadism in women

Loktionova

Ilovayskaya

2020

Alʹm. klin. med.

View full text Add to dashboard Cite

Background: Central hypogonadism (CH) is a syndrome characterized by low levels of peripheral sex steroid hormones due to the lack of central (hypothalamic-pituitary) regulation of reproductive system. In females, CH clinically manifests by amenorrhea, anovulation, and infertility. The classical diagnostic criteria of CH in the absence of organic disease of hypothalamic-pituitary region (“idiopathic” CH) include low gonadotropin levels; however, their levels within the reference ranges do not exclude CH. Moreover, reference ranges for these parameters are different between laboratories. Thus, currently no clear laboratory diagnostic criteria for female CH are available.Aim: To determine the diagnostic value of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) basal levels for the confirmation of CH diagnosis in women and to identify cutoffs of basal gonadotropins levels, which can be considered as diagnostic criteria for female CH.Materials and methods: This cross-sectional study included 87 women: 49 with confirmed CH, aged 18 to 36 years (median, 24 [Q21; Q29]), and 38 healthy fertile women with regular menstrual cycles aged 21 to 45 years (median, 23 [Q23; Q28]). In all subjects, LH, FSH, estradiol, testosterone, prolactin, and free thyroxin levels were measured by chemiluminiscent immunoassay.Results: LH, FSH, estradiol, and prolactin levels in the CH patients were significantly lower than those in healthy subjects. The ROC analysis showed that LH level ≤ 1.95 ME/l indicated the central genesis of hypogonadism with sensitivity of 81.25% and specificity of 91.89%. Basal FSH level ≤ 5.075 ME/l had a 70.00% sensitivity and 77.14% specificity for CH diagnosis.Conclusion: Basal LH level ≤ 1.95 ME/l measured by chemiluminiscent immunoassay can be considered as an idiopathic CH diagnostic criterion in female with amenorrhea due to the hypoestrogenemia with sensitivity of > 80% and specificity > 90%.

show abstract

Section: Discussionunclassified

Basal level of luteinizing hormone as a key marker of the idiopathic central hypogonadism in women

Loktionova

Ilovayskaya

2020

Alʹm. klin. med.

View full text Add to dashboard Cite

show abstract

“…На этом фоне отмечено восстановление менструального ритма, снижение уровня ПРЛ до 726 мЕд/л, что сопровождалось восстановлением овуляторных менструальных циклов (положительные результаты на овуляции по данным тест-систем). Через Наряду с нарушениями функции репродуктивной системы избыточная масса тела либо ожирение относятся к числу нередких проявлений заболевания [3]. В исследовании J. Pereira-Lima и соавт., включавшем 138 больных с гиперпролактинемией различного генеза, избыточная масса тела или ожирение выявлены у 65% пациентов [4].…”

Section: клинический портрет №3unclassified

Description of clinical portraits of patients with hyperprolactinemia

et al. 2018

View full text Add to dashboard Cite

Hyperprolactinemia is one of the most common endocrine diseases in the practice of different specialists. Interdisciplinary approach and unified principles of patient management are extremely relevant for this pathology due to the variety of clinical forms. The article demonstrates typical clinical manifestations of hyperprolactinemic syndrome on the example of three patients and shows the different approach to management and treatment.

show abstract

“…Патологическая гиперпро-лактинемия имеет распространенность 10 случаев на 100 000 населения у мужчин и 30-50 на 100 000 насе-ления у женщин [2]. Избыточная секреция пролактина, в том числе, вызывается лактотрофными опухолями -пролактиномами, на долю которых приходится около 40% всех аденом гипофиза [3].…”

Section: ожирение и метаболизмunclassified

Comparative efficacy and safety of generic (Bergolak) vs. brand cabergoline in the treatment of patients with prolactin-secreting tumors

et al. 2015

View full text Add to dashboard Cite

Objective: To evaluate the effectiveness and safety of cabergoline drug Bergolak («Veropharm», Russia) in the treatment of patients with prolactin-secreting tumors.Materials and methods: The study included 14 patients (14 women, mean age 46±12) diagnosed with prolactinoma. The patients were switched to Bergolak after 1 month of treatment by original cabergoline. Dose of cabergoline varied from 0,125 mg to 3,25 mg per week. Prolactin level, symptoms of hyperprolactinemic hypogonadism, side-effects were evaluated at the baseline, after 1 month of original cabergoline treatment and 1 and 2 months of Bergolak therapy.Results: Statistical differences in the level of prolactin (p 0.05), and the incidence of side-effects (p 0.43) during Bergolak therapy in comparison with the original drug was not registered.Conclusions: Bergolak showed to be effective drug for treatment of patients with prolactin-secreting tumors. The incidence of side-effects during Bergolak therapy is equal to the original cabergoline treatment.

show abstract

Reproduction and energy balance: the integrative role of prolactin

Cited by 10 publications

References 52 publications

Basal level of luteinizing hormone as a key marker of the idiopathic central hypogonadism in women

Basal level of luteinizing hormone as a key marker of the idiopathic central hypogonadism in women

Description of clinical portraits of patients with hyperprolactinemia

Comparative efficacy and safety of generic (Bergolak) vs. brand cabergoline in the treatment of patients with prolactin-secreting tumors

Contact Info

Product

Resources

About